TY - JOUR
T1 - T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
AU - Yoshifuji, Ayumi
AU - Toda, Masataro
AU - Ryuzaki, Munekazu
AU - Oyama, Emi
AU - Kikuchi, Kan
AU - Kawai, Toru
AU - Sakai, Ken
AU - Koinuma, Masayoshi
AU - Katayama, Kazuhiko
AU - Yokoyama, Takashi
AU - Uehara, Yuki
AU - Ohmagari, Norio
AU - Kanno, Yoshihiko
AU - Kon, Hirofumi
AU - Shinoda, Toshio
AU - Takano, Yaoko
AU - Tanaka, Junko
AU - Hora, Kazuhiko
AU - Nakazawa, Yasushi
AU - Hasegawa, Naoki
AU - Hanafusa, Norio
AU - Hinoshita, Fumihiko
AU - Morikane, Keita
AU - Wakino, Shu
AU - Nakamoto, Hidetomo
AU - Takemoto, Yoshiaki
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
AB - Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
UR - http://www.scopus.com/inward/record.url?scp=85151923192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151923192&partnerID=8YFLogxK
U2 - 10.3390/vaccines11030653
DO - 10.3390/vaccines11030653
M3 - Article
AN - SCOPUS:85151923192
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 653
ER -
